NCT04497766

Brief Summary

The purpose of study is to assess the effectiveness of nebulized magnesium sulphate in children presenting with acute asthma.Study perfoma consists of demographic variables,exclusion criteria and pediatric asthma score that includes respiratory rate,SPO2 at room air(requirement of oxygen),auscultatory findings in chest,dysnea and retractions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
148

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Oct 2019

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2019

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

July 16, 2020

Completed
19 days until next milestone

First Posted

Study publicly available on registry

August 4, 2020

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2020

Completed
Last Updated

February 23, 2021

Status Verified

February 1, 2021

Enrollment Period

1 year

First QC Date

July 16, 2020

Last Update Submit

February 19, 2021

Conditions

Keywords

asthma in childrenintravenous magnesium sulphatenebulized magnesium sulphate

Outcome Measures

Primary Outcomes (1)

  • Efficacy of nebulized magnesium sulphate with intravenous magnesium sulphate in children with acute asthma will be assessed by a drop in PAS score, as assessed at 6 hours of intervention.

    The intervention will be considered effective if there is a drop of at least 4 points in PAS score at hour-6 of intervention.

    6 hours

Secondary Outcomes (2)

  • duration of ICU stay

    72 hours/3 days

  • duration of hospital stay

    120 hours/5 days

Study Arms (2)

Nebulized magnesium sulphate

EXPERIMENTAL

100mg of mgso4 in 20ml of normal saline via ultrasonic nebulizer

Drug: Nebulized Magnesium sulfate

Intravenous magnesium sulphate

EXPERIMENTAL

Magnesium sulphate according to weight will be given intravenously.

Drug: Intravenous magnesium sulphate

Interventions

MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes

Also known as: Nebulized MgSO4
Nebulized magnesium sulphate

pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour

Also known as: IV MgSO4
Intravenous magnesium sulphate

Eligibility Criteria

Age2 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • patients with age 2 to 12 years with acute moderate to severe exacerbation of asthma as per operational definition children who are unrespoinsive to standard treatment of asthma at 60 minutes

You may not qualify if:

  • those with history of chronic lung disease and abnormal renal function contraindication for MgSO4 due to hepatic or renal disease allergy to MgSo4 children who has other comorbid illness

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King edward medical university/mayo hospital lahore

Lahore, Punjab Province, 56000, Pakistan

Location

Related Publications (8)

  • Powell C, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, Hood K, Williamson P; MAGNETIC study group. Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. Lancet Respir Med. 2013 Jun;1(4):301-8. doi: 10.1016/S2213-2600(13)70037-7. Epub 2013 Apr 22.

    PMID: 24429155BACKGROUND
  • Kokotajlo S, Degnan L, Meyers R, Siu A, Robinson C. Use of intravenous magnesium sulfate for the treatment of an acute asthma exacerbation in pediatric patients. J Pediatr Pharmacol Ther. 2014 Apr;19(2):91-7. doi: 10.5863/1551-6776-19.2.91.

    PMID: 25024668BACKGROUND
  • Goodacre S, Cohen J, Bradburn M, Gray A, Benger J, Coats T; 3Mg Research Team. Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial. Lancet Respir Med. 2013 Jun;1(4):293-300. doi: 10.1016/S2213-2600(13)70070-5. Epub 2013 May 17.

    PMID: 24429154BACKGROUND
  • Singhi S, Grover S, Bansal A, Chopra K. Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma. Acta Paediatr. 2014 Dec;103(12):1301-6. doi: 10.1111/apa.12780. Epub 2014 Oct 2.

    PMID: 25164315BACKGROUND
  • Shan Z, Rong Y, Yang W, Wang D, Yao P, Xie J, Liu L. Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta-analysis. Respir Med. 2013 Mar;107(3):321-30. doi: 10.1016/j.rmed.2012.12.001. Epub 2013 Jan 3.

    PMID: 23290189BACKGROUND
  • Alansari K, Ahmed W, Davidson BL, Alamri M, Zakaria I, Alrifaai M. Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial. Pediatr Pulmonol. 2015 Dec;50(12):1191-9. doi: 10.1002/ppul.23158. Epub 2015 Feb 4.

    PMID: 25652104BACKGROUND
  • Albuali WH. The use of intravenous and inhaled magnesium sulphate in management of children with bronchial asthma. J Matern Fetal Neonatal Med. 2014 Nov;27(17):1809-15. doi: 10.3109/14767058.2013.876620. Epub 2014 Jan 30.

    PMID: 24345031BACKGROUND
  • Daengsuwan T, Watanatham S. A comparative pilot study of the efficacy and safety of nebulized magnesium sulfate and intravenous magnesium sulfate in children with severe acute asthma. Asian Pac J Allergy Immunol. 2017 Jun;35(2):108-112. doi: 10.12932/AP0780.

    PMID: 27996280BACKGROUND

Related Links

Study Officials

  • Muhammad-Haroon Hamid, MBBS,FCPS,FRCP

    chairman /Head of department of pediatrics unit1 K.E medical university/mayo hospital l

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Post Graduate Resident in Pediatrics (MD Paeds)

Study Record Dates

First Submitted

July 16, 2020

First Posted

August 4, 2020

Study Start

October 1, 2019

Primary Completion

September 30, 2020

Study Completion

September 30, 2020

Last Updated

February 23, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

Data will be shared after publication on a reasonable request.

Locations